SynAct Pharma publishes Annual Report 2025

- Regulatory

SynAct Pharma AB (publ) (”SynAct”) (Nasdaq Stockholm: SYNACT), a clinical-stage biotechnological company focused on treating inflammation through resolution, today publishes the Annual Report for the financial year 2025. The Annual Report is attached to this press release and available on the company’s website www.synactpharma.com.

The annual report is published in Swedish and English. The Swedish annual report is also available on SynAct's website in European Single Electronic Format (ESEF).

For further information, please contact:
Jeppe Øvlesen
CEO, SynAct Pharma AB
Phone: + 45 2844 7567
E-mail: investor.relations@synactpharma.com

About SynAct Pharma AB
SynAct Pharma AB (Nasdaq Stockholm: SYNACT) is a clinical stage biotechnology company focused on the resolution of inflammation through the selective activation of the melanocortin system. The company has a broad portfolio of oral and injectable selective melanocortin agonists aimed at inducing anti-inflammatory and inflammation resolution activity to help patients achieve immune balance and overcome their inflammation. For further information: https://synactpharma.com/.

This information is information that SynAct Pharma is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication, through the agency of the contact persons set out above, at 2026-04-15 18:00 CEST.

Attachments
SynAct Pharma AB Annual Report 2025

Documents